ID   G-415
AC   CVCL_8198
SY   G415
DR   CLO; CLO_0050017
DR   BioSample; SAMN03471927
DR   cancercelllines; CVCL_8198
DR   Cell_Model_Passport; SIDM01807
DR   Cosmic; 2674060
DR   DepMap; ACH-001850
DR   RCB; RCB2640
DR   TKG; TKG 0642
DR   Wikidata; Q54835351
RX   PubMed=7429092;
RX   PubMed=11713577;
RX   PubMed=27231123;
RX   PubMed=32293552;
RX   PubMed=32899426;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 48 hours (Note=At 30th passage) (PubMed=7429092); 30 hours (PubMed=32293552).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (DepMap=ACH-001850).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DepMap=ACH-001850; RCB=RCB2640; TKG=TKG 0642
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,10
ST   D16S539: 12 (TKG=TKG 0642)
ST   D16S539: 9,12 (DepMap=ACH-001850; RCB=RCB2640)
ST   D18S51: 12,14
ST   D21S11: 32.2
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 12,14
ST   FGA: 21,24
ST   Penta D: 9
ST   Penta E: 12,14
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 15,16 (TKG=TKG 0642)
ST   vWA: 16 (DepMap=ACH-001850; RCB=RCB2640)
DI   NCIt; C3844; Gallbladder carcinoma
DI   ORDO; Orphanet_56044; Carcinoma of gallbladder and extrahepatic biliary tract
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 23
//
RX   PubMed=7429092; DOI=10.20772/cancersci1959.71.4_574;
RA   Koyama S., Yoshioka T., Mizushima A., Kawakita I., Yamagata S.,
RA   Fukutomi H., Sakita T., Kondo I., Kikuchi M.;
RT   "Establishment of a cell line (G-415) from a human gallbladder
RT   carcinoma.";
RL   Gann 71:574-575(1980).
//
RX   PubMed=11713577; DOI=10.3892/ijo.19.6.1099;
RA   Jiao W., Miyazaki K., Kitajima Y.;
RT   "Exogenous expression of E-cadherin in gallbladder carcinoma cell line
RT   G-415 restores its cellular polarity and differentiation.";
RL   Int. J. Oncol. 19:1099-1107(2001).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H.,
RA   El-Bardeesy N.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=32293552; DOI=10.1186/s40659-020-00282-7; PMCID=PMC7158131;
RA   Garcia P., Bizama C., Rosa L., Espinoza J.A., Weber H.,
RA   Cerda-Infante J., Sanchez M., Montecinos V.P., Lorenzo-Bermejo J.,
RA   Boekstegers F., Davila-Lopez M., Alfaro F., Leiva-Acevedo C.,
RA   Parra Z., Romero D., Kato S., Leal P., Lagos M., Roa J.C.;
RT   "Functional and genomic characterization of three novel cell lines
RT   derived from a metastatic gallbladder cancer tumor.";
RL   Biol. Res. 53:13.1-13.17(2020).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510; PMCID=PMC7565451;
RA   Scherer D., Davila-Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//